GSK Blood Cancer Drug Setback

News

GSK, FDA and Drug Administration

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) combinations. The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.

STAT · 2d

FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback

· 2d · on MSN

GSK falls as blood cancer drug likely headed for US rejection

STAT2d

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

GlobalData on MSN2d

FDA approves GSK’s prefilled syringe presentation of Shingrix

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.

Yahoo2mon

iTeos, GSK to shelve TIGIT drug after study setback - Yahoo

A two-drug regimen involving an experimental cancer immunotherapy from iTeos Therapeutics and GSK didn’t significantly delay tumor progression in a Phase 2 trial, leading the companies to end ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results